SummitTX Capital L.P. acquired a new stake in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report) in the 1st quarter, Holdings Channel.com reports. The institutional investor acquired 15,577 shares of the company’s stock, valued at approximately $843,000.
A number of other hedge funds also recently added to or reduced their stakes in XPH. Compass Wealth Management LLC bought a new position in shares of SPDR S&P Pharmaceuticals ETF during the 4th quarter worth about $992,000. Private Advisor Group LLC acquired a new position in shares of SPDR S&P Pharmaceuticals ETF during the first quarter valued at about $3,017,000. UBS Group AG lifted its stake in shares of SPDR S&P Pharmaceuticals ETF by 33.2% in the fourth quarter. UBS Group AG now owns 47,961 shares of the company’s stock valued at $2,686,000 after buying an additional 11,948 shares during the period. Kestra Advisory Services LLC lifted its stake in shares of SPDR S&P Pharmaceuticals ETF by 329.7% in the first quarter. Kestra Advisory Services LLC now owns 11,603 shares of the company’s stock valued at $628,000 after buying an additional 8,903 shares during the period. Finally, Stephens Inc. AR acquired a new stake in SPDR S&P Pharmaceuticals ETF during the fourth quarter worth about $229,000.
SPDR S&P Pharmaceuticals ETF Stock Up 1.5%
Shares of XPH opened at $69.74 on Friday. The stock’s 50-day moving average price is $63.63 and its 200 day moving average price is $58.91. SPDR S&P Pharmaceuticals ETF has a 12-month low of $40.80 and a 12-month high of $70.15. The firm has a market capitalization of $488.18 million, a price-to-earnings ratio of 14.28 and a beta of 0.58.
SPDR S&P Pharmaceuticals ETF Profile
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report).
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
